Literature DB >> 22231762

Melanoma in 2011: a new paradigm tumor for drug development.

Alexander M M Eggermont1, Caroline Robert.   

Abstract

Melanoma has emerged as the paradigm tumor for drug development through mutation-targeted therapies (inhibitors targeting BRAF, MEK, and c-KIT) and immunotherapy. Exploring the combinations of both approaches is a challenge that will require scientific rationale and the cooperation of the pharmaceutical industry. But, with these challenges comes another opportunity to change the paradigms in drug development.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22231762     DOI： 10.1038/nrclinonc.2011.201

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  9 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Authors:  Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

4.  Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.

Authors:  Alexander M M Eggermont; Stefan Suciu; Alessandro Testori; Wim H Kruit; Jeremy Marsden; Cornelis J Punt; Mario Santinami; François Salès; Dirk Schadendorf; Poulam Patel; Reinhard Dummer; Caroline Robert; Ulrich Keilholz; Antoine Yver; Alan Spatz
Journal:  Eur J Cancer       Date:  2011-11-05       Impact factor: 9.162

5.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

6.  KIT as a therapeutic target in metastatic melanoma.

Authors:  Richard D Carvajal; Cristina R Antonescu; Jedd D Wolchok; Paul B Chapman; Ruth-Ann Roman; Jerrold Teitcher; Katherine S Panageas; Klaus J Busam; Bartosz Chmielowski; Jose Lutzky; Anna C Pavlick; Anne Fusco; Lauren Cane; Naoko Takebe; Swapna Vemula; Nancy Bouvier; Boris C Bastian; Gary K Schwartz
Journal:  JAMA       Date:  2011-06-08       Impact factor: 56.272

7.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

Review 8.  Immunogenic and tolerogenic cell death.

Authors:  Douglas R Green; Thomas Ferguson; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

Review 9.  Improved endpoints for cancer immunotherapy trials.

Authors:  Axel Hoos; Alexander M M Eggermont; Sylvia Janetzki; F Stephen Hodi; Ramy Ibrahim; Aparna Anderson; Rachel Humphrey; Brent Blumenstein; Lloyd Old; Jedd Wolchok
Journal:  J Natl Cancer Inst       Date:  2010-09-08       Impact factor: 13.506
  9 in total
  8 in total

1.  Personalized cancer medicine: are we there yet?

Authors:  Mark Lawler; Peter Selby
Journal:  Oncologist       Date:  2013-06

Review 2.  Regulatory T cells in the immunotherapy of melanoma.

Authors:  Zhengxiao Ouyang; Hongwei Wu; Linqin Li; Yi Luo; Xianan Li; Gang Huang
Journal:  Tumour Biol       Date:  2015-10-30

3.  The P110 subunit of PI3-K is a therapeutic target of acacetin in skin cancer.

Authors:  Sung Keun Jung; Jong Eun Kim; Sung-Young Lee; Mee Hyun Lee; Sanguine Byun; Young A Kim; Tae Gyu Lim; Kanamata Reddy; Zunnan Huang; Ann M Bode; Hyong Joo Lee; Ki Won Lee; Zigang Dong
Journal:  Carcinogenesis       Date:  2013-08-02       Impact factor: 4.944

4.  Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen.

Authors:  Sandeep S Saluja; Douglas J Hanlon; Fiona A Sharp; Enping Hong; David Khalil; Eve Robinson; Robert Tigelaar; Tarek M Fahmy; Richard L Edelson
Journal:  Int J Nanomedicine       Date:  2014-11-12

5.  Clinical implications of the Hippo-YAP pathway in multiple cancer contexts.

Authors:  Han-Byul Kim; Seung-Jae Myung
Journal:  BMB Rep       Date:  2018-03       Impact factor: 4.778

6.  Benzylamine and Thenylamine Derived Drugs Induce Apoptosis and Reduce Proliferation, Migration and Metastasis Formation in Melanoma Cells.

Authors:  Marina Mojena; Adrián Povo-Retana; Silvia González-Ramos; Victoria Fernández-García; Javier Regadera; Arturo Zazpe; Inés Artaiz; Paloma Martín-Sanz; Francisco Ledo; Lisardo Boscá
Journal:  Front Oncol       Date:  2018-08-23       Impact factor: 6.244

7.  Downregulation of RNF128 activates Wnt/β-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma.

Authors:  Chuan-Yuan Wei; Meng-Xuan Zhu; Yan-Wen Yang; Peng-Fei Zhang; Xuan Yang; Rui Peng; Chao Gao; Jia-Cheng Lu; Lu Wang; Xin-Yi Deng; Nan-Hang Lu; Fa-Zhi Qi; Jian-Ying Gu
Journal:  J Hematol Oncol       Date:  2019-03-04       Impact factor: 17.388

8.  Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts.

Authors:  Giovanni Sette; Katia Fecchi; Valentina Salvati; Fiorenza Lotti; Emanuela Pilozzi; Enrico Duranti; Mauro Biffoni; Alfredo Pagliuca; Daniela Martinetti; Lorenzo Memeo; Michele Milella; Ruggero De Maria; Adriana Eramo
Journal:  J Exp Clin Cancer Res       Date:  2013-11-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.